DistantNews
Support us
Alteogen licenses subcutaneous-injection platform to Novartis in deal worth up to 4.4 trillion won
🇰🇷 South Korea /Technology

Alteogen licenses subcutaneous-injection platform to Novartis in deal worth up to 4.4 trillion won

From Chosun Ilbo · () Korean

Translated from Korean and summarized by DistantNews. Read the original for the full story.

At a glance

Press release Official statement New plan
  • Alteogen said it signed a technology-transfer agreement with Novartis for development and commercialization using its ALT-B4 platform.
  • The platform converts intravenous formulations of biologic medicines into subcutaneous injections.
  • The deal could be worth up to 4.4 trillion won.

South Korean biotech company Alteogen said it has signed a technology-transfer agreement with Swiss pharmaceutical group Novartis.

The agreement covers development and commercialization based on Alteogen’s Hybrozyme platform technology and its ALT-B4 product. The platform converts biologic medicines from intravenous formulations into subcutaneous injections.

Under the deal, Novartis will have exclusive rights to use ALT-B4 to develop and commercialize multiple biologic drugs. The agreement is valued at up to 4.4 trillion won.

About this summary

Originally published by Chosun Ilbo in Korean. Translated, summarized, and contextualized automatically by DistantNews, with a note on how the source frames the story. Not individually reviewed before publishing. How this works.

More Stories

From Our Blog